Detalhe da pesquisa
1.
Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.
Blood
; 129(8): 991-1007, 2017 02 23.
Artigo
Inglês
| MEDLINE | ID: mdl-28028022
2.
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.
Ann Hematol
; 97(8): 1453-1462, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29623394
3.
Prevalence of BCL-2/J(H) Translocation in Healthy African Americans.
Ann Hematol
; 96(1): 51-55, 2017 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-27730341
4.
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Br J Haematol
; 168(4): 507-10, 2015 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-25302557
5.
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.
Blood
; 121(16): 3147-52, 2013 Apr 18.
Artigo
Inglês
| MEDLINE | ID: mdl-23422747
6.
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.
Cancer Cell
; 12(2): 131-44, 2007 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-17692805
7.
Clonal competition with alternating dominance in multiple myeloma.
Blood
; 120(5): 1067-76, 2012 Aug 02.
Artigo
Inglês
| MEDLINE | ID: mdl-22498740
8.
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood
; 118(16): 4359-62, 2011 Oct 20.
Artigo
Inglês
| MEDLINE | ID: mdl-21860025
9.
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Blood
; 118(18): 4771-9, 2011 Nov 03.
Artigo
Inglês
| MEDLINE | ID: mdl-21860026
10.
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.
Haematologica
; 98(10): 1586-92, 2013 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23716545
11.
Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.
Br J Haematol
; 155(3): 340-8, 2011 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-21902684
12.
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
J Clin Oncol
; 36(9): 859-866, 2018 03 20.
Artigo
Inglês
| MEDLINE | ID: mdl-29381435
13.
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
Cancer Genet Cytogenet
; 169(2): 150-3, 2006 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-16938573
14.
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Cancer Res
; 62(3): 715-20, 2002 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-11830525
15.
Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Clin Cancer Res
; 21(17): 3986-94, 2015 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25991819
16.
MYC dysregulation in the progression of multiple myeloma.
Leukemia
; 34(1): 322-326, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31439946
17.
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.
Cancer Genet Cytogenet
; 132(1): 55-60, 2002 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-11801310
18.
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.
Leukemia
; 28(8): 1725-1735, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24518206
19.
Whole genome analyses of a well-differentiated liposarcoma reveals novel SYT1 and DDR2 rearrangements.
PLoS One
; 9(2): e87113, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-24505276
20.
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.
Cancer Res
; 69(8): 3579-88, 2009 Apr 15.
Artigo
Inglês
| MEDLINE | ID: mdl-19351844